Cutler Group LP Vericel Corp Call Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$30.85 - $37.09 $27,765 - $33,381	900 New	900 $3,000
Q1 2020 May 07, 2020	SELL	$7.25 - $19.22 $3,625 - $9,610	-500 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$13.77 - $19.2 $5,508 - $7,680	400 Added 400.0%	500 $0
Q3 2019 Oct 28, 2019	SELL	$14.93 - $19.83 $44,790 - $59,489	-3,000 Reduced 96.77%	100 $0
Q4 2018 Feb 05, 2019	BUY	$10.77 - $18.44 $28,002 - $47,944	2,600 Added 520.0%	3,100 $5,000
Q3 2018 Nov 07, 2018	SELL	$9.1 - $14.8 $2,730 - $4,440	-300 Reduced 37.5%	500 $0
Q2 2018 Aug 10, 2018	SELL	$9.6 - $14.6 $22,080 - $33,580	-2,300 Reduced 74.19%	800 $1,000
Q1 2018 May 11, 2018	BUY	$5.7 - $12.3 $17,100 - $36,900	3,000 Added 3000.0%	3,100 $9,000
Q3 2017 Oct 17, 2017	BUY	$3.0 - $6.0 $300 - $600	100	100 $0

276

48.4M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.79B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.